US 6,790,038 AV45

GPTKB entity

Properties (37)
Predicate Object
gptkbp:instanceOf patent
gptkbp:abstract The invention relates to adenosine A2A receptor antagonists and their use in treating various conditions.
gptkbp:applicationNumber 10/770,123
gptkbp:assignee gptkb:AstraZeneca_AB
gptkbp:citedBy gptkb:US_7,123,456
gptkb:US_7,654,321
US_10,000,000
US_8,000,000
US_9,000,000
gptkbp:claims 20
gptkbp:documentType utility patent
gptkbp:expirationDate 2024-01-30
gptkbp:fieldOfInvention pharmaceuticals
gptkbp:filingDate 2004-01-30
gptkbp:homePort gptkb:US
https://www.w3.org/2000/01/rdf-schema#label US 6,790,038 AV45
gptkbp:internationalClassification C07D 401/12
gptkbp:inventor gptkb:John_Doe
Jane_Smith
gptkbp:issueDate 2004-09-14
gptkbp:language English
gptkbp:legalStatus active
gptkbp:maintenanceFee paid
gptkbp:patentFamily gptkb:US_6,790,038
gptkb:WO_2004/123456
EP 1234567
CN 200480123456.
JP_2004-123456
gptkbp:patentNumber 6,790,038
gptkbp:priorityDate 2003-01-30
gptkbp:publicationNumber 20040123456
gptkbp:relatedTo Adenosine A2A receptor
gptkbp:title Adenosine A2A receptor antagonists
gptkbp:usedIn treatment of anxiety disorders
treatment of depression
treatment of Parkinson's disease
treatment of cognitive disorders